Displaying drugs 14801 - 14825 of 15354 in total
Perfluorodecalin
Perfluorodecalin is under investigation in clinical trial NCT03668665 (Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - a Study in "Split Wound Design").
Investigational
Matched Description: … NCT03668665 (Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and …
ABH001
ABH001 is under investigation in clinical trial NCT01749306 (A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing).
Investigational
Matched Description: … ABH001 is under investigation in clinical trial NCT01749306 (A Study of the Efficacy and Safety of ABH001 …
(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE
Experimental
4-(1H-IMIDAZOL-1-YL)PHENOL
Experimental
N-acetylsulfanilyl chloride
ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.
Investigational
Poloxalene
Ethylene oxide/propylene oxide copolymer is used as a food additive. It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).
Investigational
Vet approved
Matched Description: … These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms) …
Cimicoxib
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and …
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and …
TOP-1288
TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis).
Investigational
Matched Description: … under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and …
Rubitecan
Investigational
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. ... Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and …
3-hydroxyisoxazole-4-carboxylic acid
Experimental
4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
Experimental
Cambendazole
Experimental
Vet approved
ISIS 14803
ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell culture.
Investigational
Matched Description: … hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and …
FT-1101
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
Matched Description: … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. …
GPI-0100
GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response.
The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy.
Investigational
Matched Description: … with a variety of vaccines, has been shown to have good overall performance characteristics on safety and …
MF268
Experimental
Displaying drugs 14801 - 14825 of 15354 in total